Adia Nutrition announced that its pivotal clinical study on chronic kidney disease (CKD) has received Institutional Review Board (IRB) approval and has been submitted to ClinicalTrials.gov. The study will evaluate the safety and efficacy of Adia's proprietary AdiaVita stem cell and exosome therapy derived from umbilical cord blood in adults with moderate to advanced CKD. This randomized controlled trial aims to track kidney function and inflammation markers to provide clinical data supporting stem cell therapy in kidney disease management. Recruitment will begin soon, marking a key step in advancing regenerative treatments for CKD.
Deribit and Signalplus have launched a five-week trading competition called "The Island," running from July 6 to August 10, 2026, with a prize pool starting at 400,000 USDC and potentially growing to 600,000 USDC based on trading volume. The contest ...
David H. Lerner is accumulating shares of Meta Platforms and Micron, citing their strong long-term growth prospects driven by AI. Meta trades at a low forward P/E of about 18x with solid earnings and a strategic shift to AI cloud services and non-adv...
Crypto markets are increasingly influenced by macro factors like oil geopolitics and Bitcoin ETF outflows. Concerns over shipping disruptions near the Strait of Hormuz and OPEC+ plans to raise oil output create mixed signals for crude prices and infl...
Bitcoin's Open Interest (OI) stands at $21.11 billion, higher than altcoins' $16.36 billion, indicating strong trader focus on Bitcoin despite altcoins outperforming it recently. Analysts suggest Bitcoin's current price may be a good long-term entry ...
VAALCO Energy is increasing its oil production following the completion of the Etame drilling campaign and the start of a new joint venture with Canadian Natural Resources. Recent drilling results in Gabon have surpassed expectations, improving cash ...
